Trial reportThe Indian journal of medical research2026
Continuous alternate day vs intermittent daily fixed doses of oral isotretinoin in grade 2 acne vulgaris.
Trial report in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives The alternate day and the intermittent regimens of isotretinoin are efficacious in treating moderate acne vulgaris with low cumulative doses. The former regimen has been found to be superior in comparative studies using weight-based dosing. The fixed dosing of the two regimens has not been explored in a head-to-head trial. The objective was to compare the efficacy and safety of these regimens at fixed dosages in treating grade 2 facial acne vulgaris. Methods It was a randomised, single-blinded, non-inferiority trial. Sixty patients aged 18 years and above with grade 2 facial acne were randomised into two groups: Group A received 20 mg isotretinoin on alternate days, and Group B received 30 mg daily for one wk per month for four months. Results The mean acne load in group A and B reduced to 5.63±4.87 and 5.63±4.87 from 22.60±10 and 28.70±18.10, respectively. The percentage of participants achieving a significant response was 96.7% and 93.3% in group A and B (P=0.28). The estimates were within the non-inferiority margins. The acne load progressively decreased with greater effect size as the treatment continued. Relapse to pretreatment score was not detected. Side effects were comparable between the groups. The cost was significantly higher with the alternate regimen. Interpretation and conclusions The daily intermittent regimen is non-inferior to alternate day regimen at fixed dosages in significantly improving grade 2 facial acne vulgaris with similar side effect profiles. The daily intermittent regimen, also with a lower cost, is thus preferrable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.